No Data
A-share midday announcement: Xiaoming Co.'s chicken product sales revenue in November increased by 7.36% month-on-month.
1. Xiaoming Co., Ltd.: In November 2024, the company sold 24.1197 million chicken products, achieving sales revenue of 92.8349 million yuan, with quarter-on-quarter growth of 2.71% and 7.36%, and year-on-year growth of 26.43% and 98.04% respectively. 2. Xidian Pharmaceutical: The oral solution of levofloxacin was granted approval notification for a pharmaceutical supplementary application, changing the marketing authorization holder from "shandong longnuo pharmaceutical Co., Ltd." to "jilin province xidian pharmaceutical technology development Co., Ltd.".
Western Point Pharmaceutical (301130.SZ): The approval notice for the supplementary application of oral solution of tartrate lisdexamfetamine has been received.
Gelonghui reported on December 9 that Xidian Pharmaceutical (301130.SZ) announced that the company recently received the "Pharmaceutical Supplement Application Approval Notice" issued by the National Medical Products Administration (NMPA) for the oral solution of donepezil hydrochloride. The oral solution of donepezil hydrochloride is used to treat symptoms of mild to moderate Alzheimer's disease.
The major shareholders of Xidian Pharmaceutical (301130.SZ), Guotou Gaoke and its concerted actors, have cumulatively reduced their shareholding by 1.03%.
Western Point Pharmaceuticals (301130.SZ) announced that the shareholder holding more than 5% of the shares, Guotou High Technology Investment Co., Ltd. (simple...
Xidian Pharmaceutical (301130.SZ): The approved traditional chinese medicine products include Xinnaokang capsules and others.
Gelonghui November 26丨West Point Pharmaceutical (301130.SZ) stated on the investor interaction platform that the approved traditional chinese medicine products include Xin Naokang capsules, Yin Gan detoxification capsules, Yin Gan supporting capsules, Jiangtangning capsules, Sanqi tablets, etc. Since its establishment, the company has been committed to enhancing its brand value through measures such as product positioning, product quality, continuous innovation and development, and intellectual property protection.
Chinese Drug Regulator Accepts Jilin Province Xidian Pharma's Application to Change Alzheimer Drug's Authorization Holder; Shares Down 3%
Western medicine (301130.SZ): The company's approved pharmaceutical list does not include folic acid active pharmaceutical ingredient and folic acid tablets
On November 22, Gelonghui announced that Western Point Pharmaceuticals (301130.SZ) stated on the investor interaction platform that the approved pharmaceutical list of our company does not include active pharmaceutical ingredients of folic acid or folic acid tablets.
Does The Market Have A Low Tolerance For Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd's (SZSE:301130) Mixed Fundamentals?
